The Drug Enforcement Administration has filed a brief asking its administrative law judge to recommend moving marijuana to Schedule III, a significant procedural step in the long-running federal rescheduling review.
Read →Ongoing negotiations over reimbursement and insurance coverage for medical cannabis in Germany have become contentious, with industry and regulators at odds over the proposed framework.
Read →A multicentre, randomised, placebo-controlled phase 3 study of a standardised full-spectrum cannabis extract in chronic low back pain has been published in Nature Medicine.
Read →Researchers at the University of Sydney report that cannabidiol produced meaningful pain reductions in a trial focused on participants with nerve injury.
Read →The Therapeutic Goods Administration has published its response to a major review of unapproved medicinal cannabis products, indicating likely changes to the Special Access Scheme model.
Read →Tilray Brands has announced increased production capacity alongside commentary on evolving medical-cannabis guidance in Germany.
Read →